Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Small Profile Retriever Safely Salvages Intracranial Clots

By HospiMedica International staff writers
Posted on 15 Aug 2018
An adjustable, fully visible clot retriever is designed to retrieve blood clots provoking medium vessel occlusion (MVO) in ischemic stroke patients.

The Rapid Medical (Yokneam, Israel) Tigertriever 13 thrombectomy system is intended to restore blood flow in intracranial vessels 1-2.5 mm in diameter, which form around 30% of MVOs found in ischemic stroke patients. More...
The Tigertriever is composed of a fully recoverable, foldable wire structure made of nitinol that is mounted on a metal stem. The diameter of the mesh and the radial force on the vessel wall are mechanically adjustable using the delivery handle, thus allowing for optimal adaptability without causing stress to the vessel wall. The nitinol mesh is radiopaque for perfect visibility inside the vessels.

The system includes the handle and integrated slider, which controls mesh expansion, a locking-screw that sets the wire mesh at the selected diameter, and proximal and distal markers for confirming correct positioning of the mesh inside the vessel. Percutaneous delivery is via a neurovascular microcatheter with a soft distal outer diameter of 1.3Fr. At the end of the procedure, the mesh is removed, resulting in recanalization of the intracranial vessel. Another advantage is that it is not necessary to continue long-term antiplatelet therapy, as required in the case of stent implantation.

“Tigertriever 13 is a very important addition to the ischemic stroke device market. For the first time ever, we have a tool that is dedicated to more distal occlusions,” said Professor René Chapot, MD, head of radiology at Krupp Krankenhaus (Essen, Germany). “These occlusions can have a dramatic disabling effect on patients, and until now there was little to be done for them. Using the Tigertriever 13 we were able to retrieve clots from an MVO that was not treatable until now.”

Ischemic stroke is the most common type of stroke (85%), caused by an obstructed artery that supplies blood to the brain. For years, the gold-standard treatment was clot-busting tissue plasminogen activator (tPA), which works by dissolving the clot and improving blood flow to the section of brain being deprived of blood. However, it must be administered within four to six hours of the stroke, and is not effective in all cases.

Related Links:
Rapid Medical


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The 3D-printed microneedle patch boosts live-virus vaccine delivery (Photo courtesy of IIS/University of Tokyo)

3D-Printed Delivery System Enhances Vaccine Delivery Via Microneedle Array Patch

The COVID-19 pandemic underscored the need for efficient, durable, and widely accessible vaccines. Conventional vaccination requires trained personnel and cold-chain logistics, which can slow mass immunization... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.